Boehringer In­gel­heim plans PhI­II chron­ic kid­ney dis­ease tri­al for al­dos­terone-tar­get­ing drug af­ter mid-stage suc­cess

Boehringer In­gel­heim’s al­dos­terone syn­thase in­hibitor reached the pri­ma­ry end­point of a mid-phase chron­ic kid­ney dis­ease tri­al in com­bi­na­tion with its Eli Lil­ly-part­nered drug Jar­diance. Boehringer is now gear­ing up for a large reg­is­tra­tional tri­al to start next year.

Al­dos­terone syn­thase is an en­zyme re­spon­si­ble for mak­ing al­dos­terone, and high lev­els of this hor­mone dri­ve or­gan in­flam­ma­tion and fi­bro­sis that can lead to con­di­tions such as CKD and heart fail­ure. The place­bo-con­trolled Phase II tri­al stud­ied mul­ti­ple dos­es of Boehringer’s al­dos­terone syn­thase in­hibitor, dubbed BI 690517, with or with­out Jar­diance in 714 CKD pa­tients re­ceiv­ing sta­ble back­ground ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER